Management college in Hyderabad | Business School in Hyderabad | Narsee Monjee Institute in Hyderabad |NMIMSHyderabad

For further information please fill the details below:

First Name
Last Name
Mobile Number
Email Address
Program Enquired
School Enquired
Home > Faculty-and-research > Faculty > Full-time > Vishnu-badavath >

Dr. Vishnu N. Badavath



  

 

 Assistant Professor

 M.S. (NIPER), PhD (BIT), Post-doc (Israel).

    Specialization: Pharmaceutical Chemistry

    Experience: 7 years






Introduction

Academic

Ph.D.inPharmacy (Medicinal Chemistry), Dept. of Pharm. Sci. & Tech., Birla Institute of Technology (BIT), Ranchi, India (Sep. 2011 to Jan. 2016)

M.S. (Pharm. Med. Chemistry): NIPER-National Institute of Pharmaceutical Education and Research, Rae Bareli, India (2009 to 2011).

B. Pharmacy (Pharmaceutical Sciences): Osmania University, Hyderabad, Telangana, India.(2005-2009)

Postdoctoral Research experience:

1. Postdoctoral Research Fellow, Institute for Drug Research, The Hebrew University of Jerusalem, Israel. Sep. 2019 to Mar. 2021:

2. Postdoctoral Research Fellow, Faculty of Medicine, Chulalongkorn University, Thailand. (Jul. 2018 to Aug. 2019).

3. Postdoctoral Research Fellow, Dept. of Chemistry, Indian Institute of Technology, Banaras Hindu University (IIT-BHU). Varanasi, India. (Sep. 2017 to Jul. 2017).

4. Worked as Project Research assistant, under the supervision of Dr. T. Narender, Principal Scientist, Medicinal& Process Chemistry Division, CDRI, Lucknow, India. (Jun. 2010 to 2011

Industrial Experience:

1. Worked as Research Associate in Synthetic Research & Development, Dr. Reddy’s ILS, Hyderabad (Jun. 2016 to Aug. 2017).

2. Worked as Senior Chemist in pilot plant R & D, at Brundavan Lab. Pvt. Ltd. (Apr. 2016 to Jun. 2016)

Awarded Scholarship/Fellowships:

1. Recipient of prestigious Rachadapisaek Sompot Fund from Graduate School, Chulalongkorn University, Bangkok, Thailand. (Period: 1st July. 2018 to 31stJune 2019).

2. ReceivedIndo-MaxPlanckProjectFellow (R&D/DST/Max-Planck/MoU/LT/Che/16-17/04/part/02). from Dept. of Chemistry,Indian Institute of Technology, Banaras Hindu University. Varanasi, India.

3. CSIR-UGC-NET-June 2016, in Chemical Sciences with AIR 79 rank.

4. GATE-2009, with 88.72 percentile, conducted by Indian Institute of Technology (IIT), Roorkee, India.

5. NIPER-JEE-2009. Conducted by NIPER-Mohali, India. (Recipient of Postgraduate Fellow from Ministry of Chemicals & Fertilizers, Govt. of India (2009- 2011).

6. GPAT-2015-Conducted by All India Council for Technical Education (AICTE), New Delhi, Govt. of India.

7. Birla Institute Fellowship Award 2011-14 9 (Ph. D Entrance Exam-2011) for Pursuing Ph. D from Birla Institute of Technology (BIT)-Mesra, Ranchi,India. (Period: Sep. 2011 to Sep. 2014).

8. Post Matric Fellowship (EAMCET-2005) from Higher Technical Education, Govt. of Andhra Pradesh, 2005-2009 for pursuing B. Pharmacy from Osmania University Hyderabad, Andhra Pradesh, India

Research and Publications:-

1. Bhavya K, M. Manohar, R. Soumyajit, L. Arora, Vishnu Nayak Badavath, Madhu. S.R G.R, Suman D, Rambabu G, DurbaPal. Novel imidazo[1,2-a]pyridine derivatives induce apoptosis and cell cycle arrest in non-small cell lung cancer by activating NADPH oxidase mediated oxidative stress. Life Science 2022, 294,120334

2. Madhu R.G.R#, Badavath VN#, Velez C, Loeanurit N, Thakur A, Maddipati VC, Katari NK, Acevedo O, Boonyasuppayakorn S, Gundla R. Discovery of 3-chlorobenzyl linked 1, 9-diazaspiro [5.5] undecane derivatives, a lead for Dengue virus type 2 infection. RSC- New J. Chem., 2022, 46, 1087–1098. (IF: 3.59).

3. C. Purna Koteswara Rao, Bhaskara Rao T, Kali Charan Gulipalli, Srinu Bodige, Vishnu Nayak Badavath, et al., "Design and Synthesis of Novel Urea Derivatives of Pyrimidine-Pyrazoles as Anticancer Agents. J. Mol. Struct., 2022, 1251, 131937. (IF: 3.19).

4. Tapan Behl, Amit Gupta, Sridevi Chigurupati, Sukhbir Singh, Aayush Sehgal, Vishnu Nayak Badavath, Ahmad Alhowail, Vasudevan Mani, Saurabh Bhatia, Ahmed Al-Harrasi, Simona Bungau. Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome. Molecules.2022, 27, 1583. (IF 4.41).

5. Rajesh Ghosh#, Vishnu Nayak Badavath#, Snehasis Chowdhuri, Anik Sen. Identification of Alkaloids from Terminalia chebula as Potent SARS-CoV-2 Main Protease Inhibitors: An In Silico Perspective.Chemistry Select, 2022, 7(14), e202200055.

6. Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora, Vishnu Nayak Badavath. Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry. 2022 (Just accepted)

2021

7. Kueakulpattana, N., Wannigama, D. L., Luk-In, S., Hongsing, P., Hurst, C., Vishnu Nayak Badavath, et al., Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand.Nature-Scientific Reports,2021,11(1), 1-16. (IF: 5.13).

8. G. Suresh#, VishnuNayak Badavath#, T. Abhishek#, Na Yin#, D. J. Steven, Orlando Acevedo, Dirk Jochmans, Pieter Leyssen, Ke Wang, Johan Neyts, Tao Yujie, Galia Blum*. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS- CoV-2, a Lead Compound for Blocking COVID-19. ACS-J. Phys. Chem. Lett. 2021, 12 (7), 1793–1802 (IF: 6.74).

9. Aita, S., Badavath, V.N., Gundluru, M., Sudileti, M., Nemallapudi, B.R., Gundala, S., Zyryanov, G.V., Chamarti, N.R. and Reddy, C.S., 2021. Novel α-Aminophosphonates of Imatinib Intermediate: Synthesis, Anticancer Activity, Human Abl Tyrosine Kinase Inhibition, ADME and Toxicity Prediction.Bioorg. Chem., 2021, 109, 104718. (IF: 5.27).

10. Kaur, Dapinder, Tapan Behl, Sridevi Chigurupati, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Vishnu Nayak Badavath et al., Deciphering the focal role of endostatin in Alzheimer’s disease.Environmental Science & Pollution Research.2021, 28, 61998–62011 (IF: 4.22)

11. Alkyne-Tagged Apigenin, a Chemical Tool to Navigate Potential Targets of Flavonoid Anti-Dengue Leads. Molecule, 2021, 26 (22), 6967. (IF: 4.41).

12. Dapinder K, Tapan B, Aayush S, Sukhbir, Neelam S, Vishnu Nayak Badavath, et al., Unravelling the Potential Neuroprotective Facets of Erythropoietin for the treatment of Alzheimer’s disease. Metabolic Brain Disease. 2021, 37, 1-16 (IF: 3.58).

13. Reddivari CK, Devineni SR, Nemallapudi BR, Sravya G, Avula B, Shaik N, Badavath VN, Zyryanov GV, YellalaVenkata RR, Chamarthi NR. Design, Synthesis, biological evaluation and molecular docking studies of 1,4-disubstituted 1,2,3-triazoles: PEG-400: H2O mediated Click reaction of fluorescent organic Probes under ultrasonic irradiation. Polycycl. Aromat. Compd. 2021, 1-22 (IF: 3.74).

14.Gangireddy MS, Mantipally M, Badavath VN, Maddipati VC, Paidikondala K, Katari NK, Gundla R. Design, synthesis and molecular docking of piperidin-4-amine linked pyrimidine derivatives as potent anticancer agents. Chem. Data. Coll., 2021, 32, 100646. (IF: 2.21).

2020

15. Yasmin, S., Cerchia, C., Badavath, V.N., Laghezza, A, etal., A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects. ChemMedChem.2020, 15, 1-16 (IF: 3.46).

16. Badavath, V.N., Kumar, A., Samanta, P.K., Maji, S., Das, A., Blum, G., Jha, A. and Sen, A. Determination of Potential Inhibitors based on Isatin derivatives against SARS-Cov-2 Main protease (Mpro): A Molecular Docking, Molecular dynamics and Structure-Activity Relationship Studies. J. Biomol. Struct. Dyn. 2020, 1-19 (IF: 3.31).

17. Gundluru M, Badavath VN, Shaik HY, Sudileti M, Nemallapudi BR, Gundala S, Zyryanov GV, Cirandur SR. Design, synthesis, cytotoxic evaluation and molecular docking studies of novel thiazolyl α-aminophosphonates. Res. Chem. Intermediate.2021, 47,1139-1160 (IF: 2.91).

18. RaviJarapula, Vishnu N. Badavath, Shriram Rekulapally, Sarangapani M. Computational studies of bis-2-oxoindoline succinohydrazides and their in vitro cytotoxicity. Curr. Comput.AidedDrugDesign,2020,16(3), 270-280. (IF: 1.60).

19.Tiwari V, Badavath VN, Singh AK, Kandasamy Jeyakumar. Synthesis of photolabile group protected anomeric acetals and its application in carbohydrate synthesis with the assistance of continuous flow photo-reactor.Elsevier- J. Ind. Chem. Soc., 2020, 97, 227-236. (IF: 0.28).

20. S. S. Jadav, Vishnu Nayak Badavath*, Ramesh G, Narayana M. G, B. N. Sinha, Dominique Besson, Venkatesan J. Biological evaluation of 2-aminothiazole hybrid as antimalarial and antitrypanosomal agents: Design and synthesis. Anti-Infective Agents, 2020,18(2),101-108 (IF: 1.0).

2019

21. Saravanabhavan, M., Badavath, V.N*. Maji, S., Muhammad, S. M.Sekar. Novel halogenatedpyrido[2,3-a]carbazole with enhanced aromaticity as potent anticancer and antioxidant: Rationale design and microwave assisted synthesis. RSC-New J. Chem.2019, 43 (44), 17231-17240. 9 (IF: 3.59) .

22. Mantipally, M., Gangireddy, M.R., Gundla, R., Badavath, V.N., Mandha, S.R. and Maddipati, V.C Rational design, molecular docking and synthesis of novel homopiperazine linked imidazo[1,2 a]pyrimidine derivatives as potent cytotoxic and antimicrobial agents. Bioorg.Med. Chem. Lett. 2019.29 (16), 2248-2253. (IF: 2.82).

23. A.S. Reddy, J. Mao, L.S. Krishna, Badavath, V.N, Maji, S. Synthesis, Spectral investigation, molecular docking and biological evaluation of Cu(II), Ni(II) and Mn(II) complexes of (E)-2-((2-butyl-4-chloro-1H-imidazol-5-yl)methylene)-N-methylhydrazinecarbothioamide (C15H18N5ClS) and its DFT studies. J. Mol. Struct. 2019, 1196, 338-347 (IF. 3.19).

24. Reddy, A.S., Mao, J., Vanitha, S., Badavath, V.N., Krishna, L.S. and Lavanya, M. Synthesis, spectral characterization, molecular docking studies, biological activity of (E)-2-((E)-3-(3,4,5-trimethoxyphenyl)allylidene) and (E)-N-phenyl 2-((E)-3-(3,4,5-trimethoxyphenyl) allylidene) hydrazinecarbothioamides and their Cu(II) complexes. J. Saudi. Chem. Soc. 2019, 23 (7), 947-957. (IF. 3.93).

25. Suba, V., G. Rathika, E. Ranjith K, M. Saravanabhavan, Vishnu Nayak Badavath, K. S. Thangamani., Enhanced Adsorption and Antimicrobial Activity of Fabricated Apocynaceae Leaf Waste Activated Carbon by Cobalt Ferrite Nanoparticles for Textile Effluent Treatment. J. Inorg. Organomet. Polym. 2019, 29(2), 550-563. (IF: 3.54).

26. Gangireddy, M.R., Mantipally, M., Gundla, R., Badavath, V.N., Paidikondala, K. and Yamala, A. Design and synthesis of piperazine linked imidazo[1,2-a]pyridine derivatives as potent anticancer agents. Chemistry Select, 2019, 4 (46), 13622-13629. (IF. 2.10).

2018

27. Varsha T, Vishnu Nayak Badavath, Adesh Kumar Singh, Jeyakumar Kandasamy. A highly efficient TEMPO-mediated oxidation of sugar primary alcohols into uronic acids using 1-chloro-1, 2-benziodoxol-3(1H)-one at room temperature. Tetrahedron Lett., 2018, 59, (26), 2511–2514 (IF: 2.41).

28. Chandrani N, Vishnu N. Badavath, Abhishek Thakur, GulberkUcar, Orlando Acevedo, M.U.M. Siddique, Venkatesan Jayaprakash. Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A. Med. Chem. Commun.,2018,9, 1164-1171.(IF: 3.35).

2017

29.Vishnu Nayak Badavath*, Chandrani Nath, Narayana M. Ganta, GulberkUcar, Barij N. Sinha, Venkatesan Jayaprakash. Design, synthesis, molecular docking and MAO inhibitory activity of2-(arylmethylidene)-2,3-dihydro-1-benzofuran-3-one derivatives. Elsevier-Chinese Chemical Letters. 2017, 28 (7), 1528-1532. (IF: 6.77).

2016

30. Vishnu Nayak Badavath, IpekBaysal, GulberkUcar, B. N. Sinha,Venkatesan Jayaprakash, Monoamine oxidase inhibitory activity of novel Pyrazoline analogues: Curcumin based design and synthesis, ACS-Med. Chem. Lett., 2016, 7, 56-61. (IF: 4.34).

31. Saravanabhavan, M., Badavath, V.N*. Maji, S., Muhammad, S. and Sekar, M Novel halogenatedpyrido[2,3-a]carbazole with enhanced aromaticity as potent anticancerand antioxidant: Rationale design and microwave assisted synthesis. RSC-New J. Chem.2019, 43 (44), 17231-17240. 9 (IF. 3.59) .

32. Vishnu Nayak Badavath, G. Ucar, B. N. Sinha, S. K. Mondal, V. Jayaprakash. Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis-II. Chemistry Select, 2016, 1, 1-7. (IF: 2.10).

2015

33. Vishnu Nayak Badavath, S. C. Yabanoglu, S. Bhakat, A. K. Timiri, B.N. Sinha, G. Ucar, M. E.S. Soliman, V. Jayaprakash, Monoamine oxidase inhibitory activity of 2-aryl-4H- chromen-4-ones, Bioorg. Chem., 2015, 58, 72-80. (IF: 5.27).

34. S. S. Jadav, S. Kaptein, A. K. Timiri, Tine De B, Vishnu Nayak Badavath, Ramesh G, B. N. Sinha, Johan Neyts, Pieter Leyssen and Venkatesan J. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. Bioorg. Med. Chem. Lett., 2015, 25, 1747-1752. (IF: 2.82). ISSN:0960-894X

35. Vishnu Nayak Badavath, IpekBaysal, GulberkUcar, S. K. Mondal, B. N. Sinha, V. Jayaprakash, MAO inhibitory activity of Ferulic Acid Amides: Curcumin based design and synthesis, Wiley-Archiv der Pharmazie, 2015,348, 1-11. (IF: 3.75). ISSN:1521-4184

36. VishnuNayak Badavath, I. Baysal, G. Ucar, B. N. Sinha, S. K. Mondal, Venkatesan Jayaprakash. Monoamine oxidase-A inhibitory activity of novel Curcumin analogues. J. Pharm. Chem., 2015, 2, 12-17.ISSN: 2349-5731(Online)

37. Vishnu Nayak Badavath, A. K. Singh, S. S Jadav, N. Mishra, D. Abhimanyu, B. N. Sinha, Venkatesan J. Pyrazoline carboxylates as selective MAO-B inhibitors: Synthesis and Biological screening. J. Pharm. Chem. 2015, 2, 1-5 .ISSN: 2349-5731 (Online)

38.Vishnu Nayak Badavath*, B. N. Sinha, Venkatesan Jayaprakash, Design, in-silico docking and predictive ADME properties of novel Pyrazoline derivatives with selective human MAO inhibitory activity, Int. J. Pharm. Pharm. Sci., 2015, 7, 277-282. ISSN: 0975-1491 Online, 2656-0097 Print

39.A. K. Timiri, Vishnu Nayak Badavath, B. N. Sinha, Venkatesan J, Subasri Selvarasu, Vishwanathan Vijayan, Velmurugan Devadasan. Synthesis, spectral and crystal studies of 2-(4, 6-diamino pyrimidin-2-ylthio)-N-m/p-tolyl/3, 4-dimethylacetamides. Formulation Development and Analysis.2015, 1, 7-14.

2013

40. B. Vishnu Nayak, S. Ciftci-Yabanoglu, S. S. Jadav, Monika Jagrat, B. N. Sinha, G. Ucar, Venkatesan Jayaprakash, Monoamine oxidase inhibitory activity of 3, 5-biaryl-4, 5- dihydro-1H-pyrazole-1-carboxylate derivatives, Eur. J. Med. Chem., 2013, 69, 762-767. (IF: 6.51). ISSN:0009-4374 (print); 0223-5234 (web)

2011

41. T. Narender, K. Venkateswarlu, B. Vishnu Nayak and S. Sarkar. A new chemical access for 3'-acetyl-4'-hydroxychalcones using BF3-Et2O via a regioselective Claisen-Schmidt condensationand its application in the synthesis of chalcone hybrids, Tetrahedron Letters, 2011,52, 5794- 5798. (IF: 2.41). ISSN:0040-4039

Articles International conference proceedings:

42. Wannigama, D.L., Kueakulpattana, N., Luk-In, S., Hongsing, P., Hurst, C., Badavath, V.N., Jenjaroenpun, P., Wongsurawat, T., Teeratakulpisan, N., Kerr, S.J. and Abe, S., 2021, November. 1355. Cluster of Multi-drug Resistance Neisseria gonorrhoeae Isolates with Reduce Ceftriaxone Susceptibility, First Report in Thailand. InOpen Forum Infectious Diseases 2021, (Vol. 8, Supplement_1, S764-S764). US: Oxford University Press. (IF: 3.83). ISSN: 2328-8957

43. Reddy, A. Sreenath, L. Sivarama Krishna,Vishnu Nayak Badavath, G. Sravya, N. Bakthavatchala Reddy, and Grigory V. Zyryanov. Synthesis, spectroscopic characterization and molecular docking studies of 2-butyl-4-chloro-5-formylimidazole thiosemicarbazone cobalt (II) complex. AIP Conference Proceedings, vol. 2063, No. 1, p. 040054. AIP Publishing, 2019. (doi.org/10.1063/1.5087386).ISSN:0094-243X (print); 1551-7616 (web).

Abstracts accepted in international conference:

44. Vishnu Nayak Badavath, et al., Design, synthesis and biological screening of MAO inhibitors. Psychology, Autism and Alzheimer's disease. Sep.30-Oct. 01, 2013Hilton San Antonio Airport, TX, USA.

45. Vishnu Nayak Badavath, et al., In Modern Synthetic Methodologies for Creating Drugs and Functional Materials (MOSM2018):15-17 Nov. 2018, at Yekaterinburg, Russia.

46. Vishnu Nayak Badavath, et al., International Multidisciplinary Symposium on Drug Research & Development, Organized by Faculty of Anadolu University & Society of Researchers in Pharmacy and Medicine (ILARUD), Eskisehir, Turkiey. Oct 15-19,2015.

Vishnu Nayak Badavath, et al., Modern Synthetic Methodologies for the Creation of Medicines and Functional Materials (MOSM2018)-Ekaterinburg, 2019, Ural University Publishing House, Russia, 2020, 259-259

Patents (International: 02 /National 07):

1. US Patent (USPTO): (Complete specification US Patent Appl. No.: 17/347,261). Kobophenol A for the treatment of Corona Virus 2 (SARS-CoV-2) infection, date of priority: 14th June. 2021. Pub. No.: US2021/0388455 A1; Pub. Date: 16th Dec. 2021. Inventors/ applicant: Vishnu Nayak Badavath, Suresh Gangadevi, Na Yin, Ke wang. https://patentimages.storage.googleapis.com/30/26/c5/82de1b8c98e00c/US20210388455 A1.pdf.

2. Title: Kobophenol A for the treatment of Corona Virus 2 (SARS-CoV-2) infection (Patent Appl. No.: 202041024910, complete specification: filed on 13th June. 2020. (A complete specification submitted on 11th June 2021). Inventors/ applicant: Vishnu Nayak Badavath, Suresh Gangadevi, Na Yin, Ke wang.

3. Title: Benzofuran and pyrazole substituted 1, 3, 4-oxadiazolecompounds, compositions and Process of preparation thereof (Complete specification: Patent Appl. No.: 202111036012, date of priority: 10thAug. 2021. Inventors: Vishnu Nayak Badavath, Satish S. KOLA, Idress Mohammad, SIDDIQUI Naqui J, Sandeep Arora, Tapan Behl

4. Title: 2-amino-4H-pyran coupled imidazo[1,2-a]pyridine, their synthesis, anticancer activity and methods thereof (Complete specification: Patent Appl. No.: 202111040855, date of priority: 09thSep. 2021). Inventors: Vishnu Nayak Badavath, Rambabu Gundla, Durba Pal, Manohar Mantipally, Bhavya Kumari

5. Title: Pyrrolo[2,3-a] carbazole-2-carboxylatederivatives, their synthesis, anticancer activity and methods thereof. (Complete specification: Patent Appl. No.: 202111042979,date of priority: 22nd Sep. 2021). Inventors: Vishnu Nayak Badavath, Saravanabhavan Munusamy, Sekar Marimuthu, GUNASEKARAN Raja, Saurabh Gupta

6. Title: 3-chlorobenzyl linked 1,9-diazaspiro[5.5]undecane derivatives, their synthesis anti Dengue virus inhibitory activity and methods thereof. (Complete specification Appl. No.: 202111045712, date of priority: 07th Oct. 2021.

Inventors: Gundla Rambabu, Vishnu Nayak Badavath, Boonyasuppayakorn Siwaporn, GANGIREDDY, Madhu Sudhana Reddy

7.Anti-cancer pyrido[2,3-a]carbazole compounds, theircompositions and process of synthesis thereof. (Complete specification, Appl. No.: 202111060040, date of priority: 22 Dec. 2021). Inventors: M. Saravanabhavan, VishnuNayak Badavath, Shanmugam Ramesh, SekarMarimuthu, LESHAN WANNIGAMA

8. Title: A Quinoline anti-tubercular compound, compositions and processof preparation thereof. (Patent Appl. No.: 202111054540, date of priority: 25th Nov. 2021).

Inventors: Sandeep Arora, Ritchu Babbar, Vishnu Nayak Badavath.

9. A composition for management of SARS-CoV2 comprising delta-viniferin. (Provisional specification, (Patent Appl. No.: 202111059759,date of priority: 21st Dec. 2021). Inventors: Vishnu Nayak Badavath, Sandeep Arora, Dhammika Leshan Wannigama, Sukhbir Singh, Tapan Behl.

Book and book chapters:

1.Chapter 6: Pharmacophore modelling in drug design in edited book Computer-Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. 2022, Publisher: Elsevier, (ISBN: 9780323906081). Authors: Siddhartha Maji, Anik Sen, Vishnu Nayak Badavath*.

2. Chapter 3:MAO inhibitory activity of 4, 5-dihydro-1H-pyrazole derivatives: A platform to design novel Antidepressants, Frontiers in Drug Design and Discovery, 2020, Vol. 10, 47-91, Bentham Science Publisher, Doi:10.2174/9789811421563121100005(ISSN: 15740889, 22121060). Authors: Vishnu Nayak Badavath*, Venkatesan Jayaprakash.

3. Chapter 31: Synthetic Analogues of Curcumin: The search for Anticancer and Antioxidant activities, In book Science of spices & Culinary Herbs, Vol. 6, 1-30, Bentham Science Publishers Pte. Ltd. Singapore. ISBN (eBook):978-1-68108-751-1; (Print):978-1-68108-752-8. Authors: Vishnu Nayak Badavath*, Siddhartha Maji, Munusamy, S., V. Jayaprakash.

4.Chapter 6: Drug Repurposing and Computational Drug Discovery for Viral Infections and Corona Virus Disease 2019 (COVID-19). In Book: Drug Repurposing and Computational DrugDiscoveryStrategies and Advances. Siddhartha Maji, Vishnu Nayak Badavath, Swastika Ganguly. Apple Academy Press 2022. (Hard ISBN:9781774912775). In Production. Pub Date:Forthcoming April 2023. Pages:Est. 344pp w/ index

5.Chapter 7: Importance of in-silicotools in anticancer drug discovery from Nature. Alternative Remedies and Natural products for Cancer Therapy: An Integrative Approach, 2021, 125-164. (Accepted Manuscript).

Interest Areas:-

My research focuses on the interdisciplinary area between molecular biology and organic chemistry (organic, medicinal, and carbohydrate) design, synthesis, and screening of novel synthetic and natural based compounds for the treatment of viral infections, i.e., (SARS-CoV-2, Dengue, Chikungunya, and Enterovirus). and the designing of a novel for the treatment of various diseases (cancer, Diabetes and other central nervous system-related diseases

  • Organic/Medicinal/Carbohydrate/Natural products chemistry
  • CADD- Computer-Aided Drug Design
  • Molecular Biology and Chemical Biology
  • Activity based probes attach nanoparticles to determine theminimal tumour size detected by CT-Probes.

·Please find the attached Google Scholar link

·https://scholar.google.co.in/citations?hl=en&user=WZM2Q8YAAAAJ

·ORCID:http://orcid.org/0000-0002-6433-2691

·Scopus ID: 56463059600

·https://www.researchgate.net/profile/Vishnu-N-Badavath

 

           
© Copyright 2022. Shri Vile Parle Kelavani Mandal (SVKM) All Rights Reserved.   Disclaimer  |  Privacy Policy
TOP